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:   regulator of G protein signaling

SE

:   standard error
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:   venus

*α*2‐AR
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Introduction {#prp2249-sec-0001}
============

Canonical G protein‐coupled receptor (GPCR) signaling begins with binding of an extracellular ligand to the receptor. Upon conformational rearrangement of the GPCR, the receptor is able to stimulate the exchange of GDP for GTP in the G*α* subunit of the heterotrimeric G protein (G*αβγ*) (Bourne [1997](#prp2249-bib-0002){ref-type="ref"}). Binding of GTP by G*α* results in rearrangement and sometimes dissociation of the G*αβγ* heterotrimer, allowing both G*α* and G*βγ* to signal to downstream effector molecules (Gilman [1987](#prp2249-bib-0011){ref-type="ref"}; Hepler and Gilman [1992](#prp2249-bib-0014){ref-type="ref"}; Hamm [1998](#prp2249-bib-0012){ref-type="ref"}). Regulators of G protein signaling (RGS) proteins negatively regulate G protein signaling by serving as GTPase activating proteins (GAPs) that stimulate the intrinsic GTPase of the G*α* subunit. Upon hydrolysis of GTP to GDP, G*α* rebinds G*βγ* thereby terminating the G protein signaling event (De Vries et al. [2000](#prp2249-bib-0007){ref-type="ref"}; Ross and Wilkie [2000](#prp2249-bib-0030){ref-type="ref"}; Hollinger and Hepler [2002](#prp2249-bib-0015){ref-type="ref"}).

Many RGS proteins have a relatively simple structure, lacking domains outside the canonical RGS domain. However, other RGS proteins have a more complicated structure. One such protein, RGS14, is a multifunctional scaffold that is highly expressed in the brain (Traver et al. [2000](#prp2249-bib-0034){ref-type="ref"}; Lee et al. [2010](#prp2249-bib-0022){ref-type="ref"}; Evans et al. [2014](#prp2249-bib-0010){ref-type="ref"}), and has been identified as a natural suppressor of synaptic plasticity in CA2 hippocampal neurons and of hippocampal‐based learning and memory (Lee et al. [2010](#prp2249-bib-0022){ref-type="ref"}). As a member of the R12 family of RGS proteins, RGS14 possesses an N‐terminal RGS domain that engages G*α*i/o family members (Cho et al. [2000](#prp2249-bib-0006){ref-type="ref"}; Traver et al. [2000](#prp2249-bib-0034){ref-type="ref"}; Hollinger et al. [2001](#prp2249-bib-0016){ref-type="ref"}). In addition, RGS14 also has a C‐terminal G protein regulatory (GPR) motif (Hollinger et al. [2001](#prp2249-bib-0016){ref-type="ref"}; Kimple et al. [2001](#prp2249-bib-0019){ref-type="ref"}) and two tandem Ras/Rap‐binding domains (RBDs) (Traver et al. [2000](#prp2249-bib-0034){ref-type="ref"}). The GPR motif binds inactive G*α*i1/3 proteins while the first RBD binds activated Ras/Rap proteins (Traver et al. [2000](#prp2249-bib-0034){ref-type="ref"}; Mittal and Linder [2004](#prp2249-bib-0025){ref-type="ref"}; Willard et al. [2009](#prp2249-bib-0038){ref-type="ref"}; Shu et al. [2010](#prp2249-bib-0033){ref-type="ref"}; Vellano et al. [2013](#prp2249-bib-0036){ref-type="ref"}).

Given its unique molecular architecture, RGS14 is primed to intercept incoming G*α* signals. Previously we showed that activation of G*α*i/o proteins can recruit cytosolic RGS14 to the plasma membrane through the RGS domain (Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}). Moreover, co‐expression of inactive G*α*i1 targets RGS14 to the plasma membrane through the GPR motif (Shu et al. [2007](#prp2249-bib-0032){ref-type="ref"}; Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}) where RGS14 can form a G*α*‐dependent complex with GPCRs (Vellano et al. [2013](#prp2249-bib-0036){ref-type="ref"}). Considering these two distinct G*α*‐interacting sites, we have proposed a model of RGS14 function (Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}) in which the RGS domain "senses" G protein activation, thereby recruiting cytosolic RGS14 to the plasma membrane. At the membrane, RGS14 accelerates the GTPase of the G*α* to hydrolyze GTP to GDP. At this time, RGS14 would then be optimally positioned to bind the newly formed G*α*‐GDP through its GPR motif and form a stable complex at the plasma membrane. Alternatively, a subset of RGS14 may exist in a preformed complex with G*α*i‐GDP at the plasma membrane, independent of G*βγ*.

Previous studies have indicated that the binding of G*α* by G*βγ* and the GPR motif of RGS14 are mutually exclusive (Mittal and Linder [2006](#prp2249-bib-0026){ref-type="ref"}; Shu et al. [2007](#prp2249-bib-0032){ref-type="ref"}). In support of this idea, structural characterization demonstrated that the binding site of the RGS14 GPR motif on G*α* overlaps with that of G*βγ* (Kimple et al. [2002](#prp2249-bib-0020){ref-type="ref"}). While biochemical studies have suggested the RGS14 GPR motif cannot disrupt preformed G*αβγ* heterotrimers (Mittal and Linder [2006](#prp2249-bib-0026){ref-type="ref"}), other studies have suggested the GPR motif may prevent heterotrimer reassembly after GPCR stimulation (Webb et al. [2005](#prp2249-bib-0037){ref-type="ref"}). As such, RGS14 interference with the reassociation of G*α* with G*βγ* may prolong G*βγ* signaling. To test the idea that RGS14 might prolong G*βγ* signaling more than conventional RGS proteins, we utilized a bioluminescence resonance energy transfer (BRET) based biosensor for G*βγ* release to monitor the activation and deactivation of heterotrimeric G proteins that interact with RGS14 (G*α*o and G*α*i1). Using this biosensor, we compared RGS4, a conventional RGS protein, with the unconventional RGS14 to understand the regulation of G protein heterotrimers. We examined whether RGS14 interrupts formation of G*αβγ* heterotrimers by examining basal BRET ratios prior to agonist addition. Additionally, we examined whether BRET signals returned to baseline after antagonist addition to assess whether RGS14 disrupts heterotrimer reassembly after a signaling event.

Here, we show that co‐expression of RGS4 or RGS14 each limits the release of free G*βγ* as well as stimulates the deactivation rate of G proteins in live cells. RGS14 does not appear to interfere with formation of G*αβγ* heterotrimers either before or after receptor stimulation. Co‐expression of inactive G*α*i1 with RGS14 did not alter the GAP effect on G*α*o proteins. Based on these findings, we propose that the RGS domain and the GPR motif of RGS14 function independently in live cells.

Materials and Methods {#prp2249-sec-0002}
=====================

Cell culture and transfection {#prp2249-sec-0003}
-----------------------------

HEK 293 cells were maintained in 1× Dulbecco\'s modified Eagle\'s medium without phenol red indicator supplemented with 10% fetal bovine serum (5% after transfection), 2 mmol/L [l]{.smallcaps}‐glutamine, 100 units/mL penicillin, and 100 mg/mL streptomycin. Cells were kept in a 37°C incubator supplied with 5% CO~2~. Transfections were carried out using polyethyleneimine (PEI) as described previously (Brown et al. [2015a](#prp2249-bib-0003){ref-type="ref"}).

Constructs and reagents {#prp2249-sec-0004}
-----------------------

The hemagglutinin (HA) epitope‐tagged *α*2a‐adrenergic receptor (HA‐*α*2a‐AR) used in this study was kindly provided by Dr. Joe Blumer (Medical University of South Carolina). Hemagglutinin epitope‐tagged RGS4 (HA‐RGS4) and FLAG‐tagged RGS14 (FLAG‐RGS14) were generated as described previously (Bernstein et al. [2004](#prp2249-bib-0001){ref-type="ref"}; Shu et al. [2007](#prp2249-bib-0032){ref-type="ref"}). The pertussis‐resistant mutants (C351G) of G*α*o and G*α*i1 were purchased from the cDNA Resource Center (cDNA.org, Bloomsberg, PA). Mas‐GRK3ct‐Luc and Ven‐G*βγ* were described previously (Hollins et al. [2009](#prp2249-bib-0017){ref-type="ref"}). UK 14,304 was obtained from Sigma‐Aldrich (St. Louis, MO) while rauwolscine was purchased from Tocris Bioscience (Bristol, United Kingdom). Pertussis toxin was purchased from List Biological Laboratories, Inc (Campbell, CA).

Kinetic BRET assay {#prp2249-sec-0005}
------------------

For kinetic BRET experiments, HEK 293 cells seeded in six‐well plates were transfected with 25 ng mas‐GRK3ct‐Luc, 200 ng HA‐*α*2A‐AR, 200 ng Ven‐G*β*1, 200 ng Ven‐G*γ*2, and 400 ng of either G*α*o‐C351G or G*α*i1‐C351G. HA‐RGS4 or FLAG‐RGS14 was also transfected in 3, 10, 30, and 100 ng amounts. For each experiment, a control using pertussis‐sensitive G*α*o or G*α*i1 was included to record any noise within the system. Pertussis toxin (100 ng/mL) was added at the time of transfection to limit activation of endogenous G proteins. Cells were transfected for 24 h before resuspension in Tyrode\'s solution (140 mmol/L NaCl, 5 mmol/L KCl, 1 mmol/L MgCl~2~, 1 mmol/L CaCl~2~, 0.37 mmol/L NaH~2~PO~4~, 24 mmol/L NaHCO~3~, 10 mmol/L HEPES, and 0.1% glucose, pH 7.4) and plated on white 96‐well Optiplates (Perkin Elmer Life Sciences, Waltham, MA). Fluorescence measurements to confirm acceptor expression were made using the TriStar LB 941 plate reader (Berthold Technologies, Bad Wildbad, Germany) with 485‐nm excitation and 530‐nm emission filters. After a 5 min application of 5 *μ*mol/L coelenterazine H (Nanolight Technologies, Pinetop, AZ), kinetic BRET was monitored using sequential measurements through 485‐ and 530‐nm emission filters. BRET was recorded for 30 sec with no stimulation to establish basal BRET. After basal BRET measurements, agonist was applied for 60 sec followed by 90 sec of antagonist application. The change in BRET (ΔBRET) was calculated by dividing the mas‐GRK3ct‐Luc signal (530 nm) by the Ven‐G*βγ* signal (485 nm) and subtracting the average BRET signal observed from the first 30 sec of observation (basal BRET). With each experiment, a kinetic BRET control was performed utilizing pertussis‐sensitive G*α* to ensure the effectiveness of the pertussis toxin. Any signal recorded in these controls was regarded as noise and subtracted from experimental kinetic BRET recordings. Data were collected using the MikroWin 2000 software (Mikrotek Laborsysteme GmbH, Overath, Germany) and analyzed using Microsoft Excel and GraphPad Prism 5. Deactivation curves were fitted to a single‐phase decay exponential function. Statistical data analysis was performed using a one‐way analysis of variance (ANOVA) with Tukey\'s or Dunnett\'s post hoc test where indicated.

Immunoblotting {#prp2249-sec-0006}
--------------

Representative immunoblots were performed using primary antibodies for *α*2A‐AR, G*α*o, and G*α*i1 from Santa Cruz Biotechnology. Primary GFP antibodies (MBL International) were used to detect Venus‐G*β* expression while mas‐GRK3ct‐Luc expression was assessed with the anti‐Luciferase antibody from Millipore. HRP‐conjugated FLAG antibodies (Sigma) were used to detect FLAG‐tagged RGS14 constructs. Proteins were then detected with enhanced chemiluminescence.

Results {#prp2249-sec-0007}
=======

Activation of *α*2a‐AR releases free G*βγ* from G*α*o and G*α*i1 proteins {#prp2249-sec-0008}
-------------------------------------------------------------------------

The goal of these studies was to compare the regulation of G protein activation and deactivation and G*βγ* signaling in live cells by a conventional RGS protein (RGS4) and an unconventional RGS protein containing a second G protein‐binding GPR motif (RGS14). Ideally, this would involve measuring the real‐time kinetics of G*α* and G*βγ* dissociation and reassociation directly in live cells. Our initial studies attempted this using a live cell BRET assay with luciferase‐tagged G*α*i (G*α*i‐Luc) and a Venus‐tagged G*βγ* (G*βγ*‐Ven), activated with an appropriate G*α*i/o‐coupled GPCR. However, we were unable to detect significant heterotrimer dissociation following receptor activation using this assay (data not shown), consistent with previous reports of G protein heterotrimer rearrangement in cells (Bunemann et al. [2003](#prp2249-bib-0005){ref-type="ref"}; Hepler [2014](#prp2249-bib-0013){ref-type="ref"}).

As an alternative approach, we took advantage of a previously reported live cell biosensor assay for G*βγ* activation that involves transfecting into cells a GPCR, G*α* protein, G*βγ*, and a biosensor for G*βγ* activation (Fig. [1](#prp2249-fig-0001){ref-type="fig"}A). The biosensor for G*βγ* activation, designated as mas‐GRK3ct‐Luc (Hollins et al. [2009](#prp2249-bib-0017){ref-type="ref"}), features the C‐terminal G*βγ*‐binding region of G protein‐coupled receptor kinase 3 (GRK3). A myristate attachment sequence (mas) was attached to the N‐terminus of the GRK3 G*βγ*‐binding domain while Renilla Luciferase (RLuc8) was attached to the C‐terminus. The mas sequence allows the G*βγ* biosensor to be targeted to the plasma membrane while the Luciferase tag serves as a BRET donor. A bimolecular fluorescence complementation technique was employed to generate a Venus‐G*β*1*γ*2 BRET acceptor. Residues 156--239 of Venus were fused to the N‐terminus of G*β*1 while residues 1--155 of Venus were fused to the N‐terminus of G*γ*2. Upon heterodimerization, the Venus‐tagged G*β*1*γ*2 constructs form a functional G*βγ* subunit (Hollins et al. [2009](#prp2249-bib-0017){ref-type="ref"}; Hynes et al. [2011](#prp2249-bib-0018){ref-type="ref"}). We chose this G*βγ* biosensing system because the mas‐GRK3ct‐Luc biosensor provides a clear indication of heterotrimer activation (Hollins et al. [2009](#prp2249-bib-0017){ref-type="ref"}; Masuho et al. [2015a](#prp2249-bib-0023){ref-type="ref"},[b](#prp2249-bib-0024){ref-type="ref"}). Additionally, we chose the *α*2A‐adrenergic receptor as we have studied it previously and demonstrated that RGS14 can associate with the receptor in a G*α*i1‐dependent manner (Vellano et al. [2011](#prp2249-bib-0035){ref-type="ref"}, [2013](#prp2249-bib-0036){ref-type="ref"}).

![G*α*o releases more free G*βγ* than G*α*i1 following receptor activation. (A) Schematic representation of kinetic BRET experiment. Venus‐tagged G*β*1 and G*γ*2 form a dimer that binds inactive G*α*‐GDP. Addition of *α*2A‐adrenergic receptor agonist UK 14,304 stimulates G*α* to bind GTP and releases Venus‐G*βγ*. During the activation phase, free Venus‐G*βγ* binds the mas‐GRK3ct‐Luc to produce a rise in BRET. Addition of rauwolscine halts the activation of G*α* proteins. During the deactivation phase, G*α* hydrolyzes GTP to GDP and reforms a heterotrimer with G*βγ*, quenching the BRET signal. (B) HEK 293 cells were transfected with 200 ng of *α*2A‐adrenergic receptor, 200 ng of Venus‐G*β*1, 200 ng of Venus‐G*γ*2, 25 ng of mas‐GRK3ct‐Luc, and 400 ng of either G*α*o or G*α*i1. Baseline BRET was measured for 30 sec prior to addition of agonist. Alpha2A‐AR agonist (1 *μ*mol/L UK 14,304) was added for 60 sec followed by a 90 sec application of antagonist (100 *μ*mol/L rauwolscine). Data are expressed as average whole traces of BRET in cells expressing G*α*o (blue, *n* = 3) and G*α*i1 (black, *n* = 4).](PRP2-4-e00249-g001){#prp2249-fig-0001}

HEK 293 cells were transfected with the *α*2A‐adrenergic receptor (*α*2A‐AR), mas‐GRK3ct‐Luc, Venus‐G*βγ* and either G*α*o or G*α*i1, each containing a mutation conferring pertussis toxin‐resistance (C351G) and then treated with pertussis toxin to eliminate signaling contributions from endogenous G proteins. Addition of *α*2a‐AR agonist UK 14,304 (1 *μ*mol/L) activates the G protein heterotrimer and produces dissociation of the G*α* and G*βγ* subunits. Free G*βγ* binds the G*βγ* activation biosensor as indicated by the rise in ΔBRET (Fig. [1](#prp2249-fig-0001){ref-type="fig"}B). After 60 sec of agonist application, addition of *α*2a‐AR antagonist rauwolscine (100 *μ*mol/L) rapidly halts activation of G proteins and allows G*α* proteins to hydrolyze GTP to GDP. G*βγ* dissociates from the G*βγ* biosensor to reform a heterotrimer with G*α* as indicated by a decrease in ΔBRET.

Agonist‐induced activation of G*α*o proteins generated a larger ΔBRET than G*α*i1. Cells expressing G*α*o produced a maximum ΔBRET of 0.129 (±0.020 SE) while cells expressing G*α*i1 produced a maximum ΔBRET of 0.040 (±0.002 SE) (Fig. [1](#prp2249-fig-0001){ref-type="fig"}B). These results are consistent with other reports suggesting G*α*i1 proteins do not release as much free G*βγ* as G*α*o proteins (Digby et al. [2008](#prp2249-bib-0008){ref-type="ref"}; Masuho et al. [2015b](#prp2249-bib-0024){ref-type="ref"}).

Expression of RGS4 reduces the release of free G*βγ* and accelerates the deactivation rate of G proteins {#prp2249-sec-0009}
--------------------------------------------------------------------------------------------------------

To determine the effect of an RGS protein on free G*βγ* release, we co‐expressed increasing amounts of RGS4 (Figs. [2](#prp2249-fig-0002){ref-type="fig"}A, [3](#prp2249-fig-0003){ref-type="fig"}A). We chose RGS4 because it is a well‐studied RGS protein that features a relatively simple protein structure, lacking domains outside the RGS domain. In cells expressing G*α*o, expression of 100 ng of RGS4 significantly reduced the maximum ΔBRET from 0.112 (±0.010 SE) to 0.078 (±0.003 SE, *P* \< 0.01) (Fig. [2](#prp2249-fig-0002){ref-type="fig"}B). In cells expressing G*α*i1, co‐expression of RGS4 did not result in a significant decrease in maximum ΔBRET though a trend appears to be present (Fig. [3](#prp2249-fig-0003){ref-type="fig"}B).

![RGS4 reduces the release of free G*βγ* and accelerates the deactivation of G*α*o proteins following receptor activation. (A) HEK 293 cells were transfected with 200 ng of *α*2A‐adrenergic receptor, 200 ng of Venus‐G*β*1, 200 ng of Venus‐G*γ*2, 25 ng of mas‐GRK3ct‐Luc, and 400 ng of G*α*o and monitored for kinetic BRET as in Figure [1](#prp2249-fig-0001){ref-type="fig"}. Average whole traces of BRET signal over time are shown from cells expressing G*α*o alone and 3, 10, 30, or 100 ng of HA‐RGS4 (*n* = 3). (B) Maximum ΔBRET observed from data presented in (A). (C) Deactivation curves normalized to maximum BRET and fit using a single exponential decay function. (D) Deactivation rates (*k* ~deactivation~) determined from curves fit in (C). Error bars represent ± S.E. Statistical analysis was performed using a one‐way analysis of variance (ANOVA) with Tukey\'s post hoc test (\**P* \< 0.05, \*\**P* \< 0.01).](PRP2-4-e00249-g002){#prp2249-fig-0002}

![RGS4 accelerates the deactivation of G*α*i1 proteins following receptor activation. (A) HEK 293 cells were transfected with 200 ng of *α*2A‐adrenergic receptor, 200 ng of Venus‐G*β*1, 200 ng of Venus‐G*γ*2, 25 ng of mas‐GRK3ct‐Luc, and 400 ng of G*α*i1 and monitored for kinetic BRET as in Figure [1](#prp2249-fig-0001){ref-type="fig"}. Average whole traces of BRET signal over time are shown from cells expressing G*α*i1 alone and 3, 10, 30, or 100 ng of HA‐RGS4 (*n* = 3). (B) Maximum ΔBRET observed from data presented in (A). (C) Deactivation curves normalized to Maximum BRET and fit using a single exponential decay function. (D) Deactivation rates (*k* ~deactivation~) determined from curves fit in (C). Error bars represent ± S.E. Statistical analysis was performed using a one‐way analysis of variance (ANOVA) with Tukey\'s post hoc test (\**P* \< 0.05, \*\**P* \< 0.01).](PRP2-4-e00249-g003){#prp2249-fig-0003}

We then examined the effect of an RGS on G protein deactivation. The association of G*βγ* with the biosensor is governed by the activation state of G*α*. Upon heterotrimer activation and formation of G*α*‐GTP, G*βγ* is released and binds the G*βγ* biosensor. Upon hydrolysis of GTP to GDP, G*α*‐GDP regains affinity for G*βγ* and G*βγ* dissociates from the biosensor to reassociate with G*α*‐GDP. As G*βγ* association with the biosensor is directly tied to the activation state of G*α*, the deactivation rate serves as an indirect measure of the G*α* GTPase rate (Lambert et al. [2010](#prp2249-bib-0021){ref-type="ref"}). To determine the deactivation rate, we fit the BRET curve dissociation phase with a single‐phase exponential decay function (Figs. [2](#prp2249-fig-0002){ref-type="fig"}C, [3](#prp2249-fig-0003){ref-type="fig"}C).

In cells expressing G*α*o alone, the deactivation rate was determined to be 0.057 sec^−1^ (±0.004 SE) (Fig. [2](#prp2249-fig-0002){ref-type="fig"}D). In cells expressing 100 ng RGS4, the deactivation rate increased significantly to 0.095 sec^−1^ (±0.006 SE, *P* \< 0.01). In cells expressing G*α*i1, 100 ng of RGS4 expression significantly increased the deactivation rate from 0.044 sec^−1^ (±0.001 SE) to 0.083 sec^−1^ (±0.005 SE, *P* \< 0.01) (Fig. [3](#prp2249-fig-0003){ref-type="fig"}D). These results correspond with the decreased maximum ΔBRET observed in Figures [2](#prp2249-fig-0002){ref-type="fig"}B, [3](#prp2249-fig-0003){ref-type="fig"}B and highlight the utility of the G*βγ* biosensor in detecting free G*βγ* release.

Expression of RGS14 reduces the release of free G*βγ* and accelerates the deactivation rate of G proteins {#prp2249-sec-0010}
---------------------------------------------------------------------------------------------------------

We then sought to compare the effects of RGS14 with RGS4 on the release of G*βγ* and deactivation rate. Unlike most RGS proteins including RGS4, RGS14 contains tandem RBDs and a GPR motif in addition to the RGS domain that could regulate the RGS14 effects on G protein heterotrimer activity. Similar to RGS4 (Figs. [2](#prp2249-fig-0002){ref-type="fig"}, [3](#prp2249-fig-0003){ref-type="fig"}), increasing expression of RGS14 reduced the maximum ΔBRET observed in both G*α*o‐ and G*α*i1‐expressing cells (Figs. [4](#prp2249-fig-0004){ref-type="fig"}A, [5](#prp2249-fig-0005){ref-type="fig"}A). In cells expressing G*α*o, co‐expression of 100 ng of RGS14 decreased the maximum ΔBRET from 0.129 (±0.020 SE) to 0.023 (±0.009 SE, *P* \< 0.01) (Fig. [4](#prp2249-fig-0004){ref-type="fig"}B). Similar results were obtained in cells expressing G*α*i1 where the maximum ΔBRET recorded for G*α*i1 decreased from 0.040 (±0.002 SE) to 0.014 (±0.001 SE *P* \< 0.05) in cells co‐expressing 100 ng RGS14 (Fig. [5](#prp2249-fig-0005){ref-type="fig"}B). These results indicate that RGS14 limits the release of free G*βγ* from both G*α*o and G*α*i1 proteins.

![RGS14 expression reduces the release of free G*βγ* and accelerates the deactivation of G*α*o proteins following receptor activation. (A) HEK 293 cells were transfected with 200 ng of *α*2A‐adrenergic receptor, 200 ng of Venus‐G*β*1, 200 ng of Venus‐G*γ*2, 25 ng of mas‐GRK3ct‐Luc, and 400 ng of G*α*o and monitored for kinetic BRET as in Figure [1](#prp2249-fig-0001){ref-type="fig"}. Average whole traces of BRET signal over time are shown from cells expressing G*α*o alone and 3, 10, 30, or 100 ng of FLAG‐RGS14 (*n* = 3). (B) Maximum ΔBRET observed from data presented in (A). (C) Deactivation curves normalized to maximum ΔBRET and fit using a single exponential decay function. (D) Deactivation rates (*k* ~deactivation~) determined from curves fit in (C). (E) Average BRET measured for 30 sec at baseline, prior to agonist stimulation. Error bars represent ± S.E. Statistical analysis was performed using a one‐way analysis of variance (ANOVA) with Tukey\'s post hoc test (\**P* \< 0.05, \*\**P* \< 0.01).](PRP2-4-e00249-g004){#prp2249-fig-0004}

![RGS14 reduces the release of free G*βγ* and accelerates the deactivation of G*α*i1 proteins following receptor activation. (A) HEK 293 cells were transfected with 200 ng of *α*2A‐adrenergic receptor, 200 ng of Venus‐G*β*1, 200 ng of Venus‐G*γ*2, 25 ng of mas‐GRK3ct‐Luc, and 400 ng of G*α*i1 and monitored for kinetic BRET as in Figure [1](#prp2249-fig-0001){ref-type="fig"}. Average whole traces of BRET signal over time are shown from cells expressing G*α*i1 alone and 3, 10, 30, or 100 ng of FLAG‐RGS14 (*n* = 4). (B) Maximum ΔBRET observed from data presented in (A). (C) Deactivation curves normalized to maximum BRET and fit using a single exponential decay function. (D) Deactivation rates (*k* ~deactivation~) determined from curves fit in (C). (E) Average BRET measured for 30 sec at baseline, prior to agonist stimulation. Error bars represent ± S.E. Statistical analysis was performed using a one‐way analysis of variance (ANOVA) with Tukey\'s post hoc test (\**P* \< 0.05, \*\*\**P* \< 0.001).](PRP2-4-e00249-g005){#prp2249-fig-0005}

Next, we determined the deactivation kinetics of G proteins in response to RGS14 expression (Figs. [4](#prp2249-fig-0004){ref-type="fig"}C, [5](#prp2249-fig-0005){ref-type="fig"}C). In conditions transfected with 100 ng of RGS14, the ΔBRET was not large enough to reliably fit the deactivation curve, thus we limited this analysis to conditions transfected with 0, 3, 10, and 30 ng of RGS14. In cells expressing G*α*o, the deactivation rate was 0.067 sec^−1^ (±0.006 SE) (Fig. [4](#prp2249-fig-0004){ref-type="fig"}D). Co‐expression of 30 ng of RGS14 significantly increased the deactivation rate to 0.120 sec^−1^ (±0.006 SE, *P* \< 0.05), indicative of RGS14 GAP activity. In cells expressing G*α*i1, the deactivation rate was 0.049 sec^−1^ (±0.003 SE) which increased to 0.080 sec^−1^ (±0.004 SE) upon co‐expression of 30 ng of RGS14 (Fig. [5](#prp2249-fig-0005){ref-type="fig"}D).

RGS14 does not interrupt formation of G*αβγ* heterotrimers {#prp2249-sec-0011}
----------------------------------------------------------

To assess whether RGS14 alters the formation of G*αβγ* heterotrimers prior to agonist stimulation, we then examined the basal BRET. As the GPR motif only interacts with G*α*i1/3 proteins, we did not expect RGS14 to alter basal BRET of G*α*o proteins. Prior to activation with receptor agonist, we recorded a basal ΔBRET value of 0.00 (±0.003 SE). Upon expression of RGS14, no significant difference in basal ΔBRET values was observed across a range of increasing RGS14 amounts (Fig. [4](#prp2249-fig-0004){ref-type="fig"}E). For G*α*i1, we observed a basal ΔBRET value of 0.00 (±0.004 SE) and no significant difference was observed upon expression of increasing amounts of RGS14 (Fig. [5](#prp2249-fig-0005){ref-type="fig"}E). These results suggest co‐expression of RGS14 does not alter the basal formation of G*αβγ* heterotrimers.

Additionally, based on previous observations (Webb et al. [2005](#prp2249-bib-0037){ref-type="ref"}; Mittal and Linder [2006](#prp2249-bib-0026){ref-type="ref"}), we predicted that RGS14 may be able to interfere with the capacity of the G*α*i1 and G*βγ* subunits to reform a heterotrimer. If RGS14 binding to G*α*i1 through the GPR motif prevented G*βγ* from rebinding G*α*i1, we would not expect the ΔBRET to return to baseline after addition of antagonist. Upon examination of deactivation curves, we did not observe any significant difference in the return to baseline after addition of antagonist. These results suggest that RGS14 does not interfere with heterotrimer reformation after receptor stimulation.

RGS‐null mutant of RGS14 cannot accelerate GTPase while the GPR‐null RGS14 mutant retains GAP activity {#prp2249-sec-0012}
------------------------------------------------------------------------------------------------------

Next, to elucidate the roles of the RGS domain and GPR motif on heterotrimer kinetics, we employed RGS‐null and GPR‐null mutants of RGS14 (Fig. [6](#prp2249-fig-0006){ref-type="fig"}). To examine whether the accelerated deactivation rates were due to the RGS domain, we employed an RGS‐null mutation of RGS14 (E92A/N93A). In cells expressing G*α*o, co‐expression of 30 ng RGS‐null RGS14 resulted in a deactivation rate of 0.065 sec^−1^ (±0.009 SE), which did not differ from G*α*o alone. Moreover, expression of a GPR‐null mutant of RGS14 (Q515A/R516A) increased the deactivation rate to 0.132 sec^−1^ (±0.012 SE), which did not differ from RGS14‐WT. Similar results were obtained in cells co‐expressing RGS14 mutants with G*α*i1 proteins (Fig. [7](#prp2249-fig-0007){ref-type="fig"}). Expression of 30 ng of RGS‐null RGS14 resulted in a deactivation rate of 0.052 sec^−1^ (±0.004 SE), which did not differ from G*α*i1 alone. Expression of 30 ng of GPR‐null RGS14 resulted in a deactivation rate of 0.093 sec^−1^ (±0.009 SE), which did not differ from RGS14‐WT.

![RGS14 accelerates the deactivation of G*α*o proteins through its RGS domain following receptor activation. (A) HEK 293 cells were transfected with 200 ng of *α*2A‐adrenergic receptor, 200 ng of Venus‐G*β*1, 200 ng of Venus‐G*γ*2, 25 ng of mas‐GRK3ct‐Luc, and 400 ng of G*α*o and monitored for kinetic BRET as in Figure [1](#prp2249-fig-0001){ref-type="fig"}. Deactivation curves were normalized to Maximum BRET and fit using a single exponential decay function in cells expressing G*α*o and either 0 ng or 30 ng FLAG‐RGS14‐WT (*n* = 3). (B) Deactivation curves as in (A) in cells expressing G*α*o and either 0 ng or 30 ng FLAG‐RGS14‐E92A/N93A (*n* = 3). (C) Deactivation curves as in (A) in cells expressing G*α*o and either 0 ng or 30 ng FLAG‐RGS14‐Q515A/R516A (*n* = 3). (D) Deactivation rates (*k* ~deactivation~) determined from curves fit in (A, B, and C). Error bars represent ± S.E. Statistical analysis was performed using a one‐way analysis of variance (ANOVA) with Dunnett\'s post hoc test (\**P* \< 0.05, \*\**P* \< 0.01).](PRP2-4-e00249-g006){#prp2249-fig-0006}

![RGS14 accelerates the deactivation of G*α*i1 proteins through its RGS domain following receptor activation. (A) HEK 293 cells were transfected with 200 ng of *α*2A‐adrenergic receptor, 200 ng of Venus‐G*β*1, 200 ng of Venus‐G*γ*2, 25 ng of mas‐GRK3ct‐Luc, and 400 ng of G*α*i1 and monitored for kinetic BRET as in Figure [1](#prp2249-fig-0001){ref-type="fig"}. Deactivation curves were normalized to maximum BRET and fit using a single exponential decay function in cells expressing G*α*i1 and either 0 ng or 30 ng FLAG‐RGS14‐WT (*n* = 3). (B) Deactivation curves as in (A) in cells expressing G*α*i1 and either 0 ng or 30 ng FLAG‐RGS14‐E92A/N93A (*n* = 3). (C) Deactivation curves as in (A) in cells expressing G*α*i1 and either 0 ng or 30 ng FLAG‐RGS14‐Q515A/R516A (*n* = 3). (D) Deactivation rates (*k* ~deactivation~) determined from curves fit in (A, B, and C). Error bars represent ± S.E. Statistical analysis was performed using a one‐way analysis of variance (ANOVA) with Dunnett\'s post hoc test (\*\**P* \< 0.01, \*\*\**P* \< 0.001). RGS, Regulators of G protein signaling.](PRP2-4-e00249-g007){#prp2249-fig-0007}

RGS14 GAP function on G*α*o is unaltered by GPR binding of G*α*i1 {#prp2249-sec-0013}
-----------------------------------------------------------------

Our previous investigations of RGS14 revealed that, when bound to an inactive G*α* at the GPR motif, RGS14 undergoes conformational rearrangements within the RGS domain (Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}). Upon measurement of RGS domain function utilizing in vitro GTPase assays, the preformed RGS14:G*α*i1‐GDP complex showed no difference in its ability to catalyze GTPase activity in G*α*o when compared to apo‐RGS14 (Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}). Thus, despite binding an inactive G protein to the GPR motif, RGS14 retained RGS function to stimulate the GTPase of a second G*α* at the RGS domain (Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}). Moreover, we were able to demonstrate the capacity of RGS14 to form a ternary complex with an inactive G*α* at the GPR motif and an active G*α* at the RGS domain (Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}).

To further demonstrate the role of the GPR motif in regulating RGS function in live cells, we examined whether co‐expression of G*α*i1 altered RGS14 effects on G*α*o heterotrimers (Fig. [8](#prp2249-fig-0008){ref-type="fig"}A). For these experiments, we utilized pertussis‐resistant G*α*o and pertussis‐sensitive G*α*i1 proteins to ensure that the recorded signal was due to G*α*o activation. As a control, we examined the interaction with RGS14 and G*α*i1 in the presence and absence of pertussis toxin. While treatment with pertussis toxin uncouples G proteins from GPCRs, pertussis toxin treatment did not alter the interaction between G*α*i1 and the GPR motif of RGS14 (Fig. [8](#prp2249-fig-0008){ref-type="fig"}B).

![RGS14 GAP function on G*α*o is unaltered by GPR binding of G*α*i1. (A) Schematic representation of BRET experiment. Expression of inactive G*α*i1 recruits RGS14 to the plasma membrane through the GPR motif. Agonist binding of the *α*2A‐adrenergic receptor activates the heterotrimeric G protein. Venus‐G*β*1*γ*2 binds mas‐GRK3ct to produce a rise in the BRET signal. RGS14 placement at the plasma membrane may accelerate GTP hydrolysis by G*α*o. (B) HEK 293 cells were transfected with 10 ng RGS14‐Luc and 0, 50, 100, 250, 500, or 750 ng of G*α*i1‐YFP in the presence or absence of 100 ng/mL of pertussis toxin. BRET ratios were recorded, and net BRET was calculated by subtracting the BRET signal from the luciferase alone (*n* = 3). (C) Representative immunoblots for HEK 293 cells transfected with 200 ng of *α*2A‐adrenergic receptor, 200 ng of Venus‐G*β*1, 200 ng of Venus‐G*γ*2, 25 ng of mas‐GRK3ct‐Luc, 400 ng of pertussis‐resistant G*α*o as well as 10 ng of FLAG‐RGS14/FLAG‐RGS14‐515/516 and 300 ng of pertussis‐sensitive G*α*i1 where indicated. (D) Kinetic BRET was monitored for as in Figure [1](#prp2249-fig-0001){ref-type="fig"} (*n* = 4). (E) Maximum ΔBRET observed from data presented in (D). (F) Deactivation curves were normalized to Maximum BRET and fit using a single exponential decay function (*n* = 4). (G) Deactivation rates (*k* ~deactivation~) were determined from curves fit in (D). (H) Average BRET measured for 30 sec at baseline, prior to agonist stimulation. Error bars represent ± S.E. Statistical analysis was performed using a one‐way analysis of variance (ANOVA) with Tukey\'s post hoc test. GAP, GTPase activating protein; GPR, G protein regulatory.](PRP2-4-e00249-g008){#prp2249-fig-0008}

In cells expressing G*α*o, co‐expression of 10 ng of RGS14 (Fig. [8](#prp2249-fig-0008){ref-type="fig"}C) resulted in a maximum ΔBRET of 0.0862 (±0.006 SE) (Fig. [8](#prp2249-fig-0008){ref-type="fig"}D and E). Upon co‐expression of RGS14 and 300 ng of pertussis‐sensitive G*α*i1, the observed maximum ΔBRET was 0.0830 (±0.007 SE) (Fig. [8](#prp2249-fig-0008){ref-type="fig"}D and E), demonstrating no difference from RGS14 expressed alone. Co‐expression of a GPR‐null (RGS14‐515/516) confirmed the observed effect on ΔBRET was due to an intact RGS domain (Fig. [8](#prp2249-fig-0008){ref-type="fig"}E). Additionally, the enhanced deactivation rate observed with expression of RGS14 was unchanged with co‐expression of G*α*i1. In cells expressing RGS14 alone, the observed deactivation rate was 0.110 sec^−1^ (±0.009 SE) while cells expressing RGS14 and 300 ng of pertussis‐sensitive G*α*i1 demonstrated an observed deactivation rate of 0.1023 sec^−1^ (±0.009 SE) (Fig. [8](#prp2249-fig-0008){ref-type="fig"}F and G). Co‐expression of either RGS14 or RGS14 and G*α*i1 did not alter the basal BRET (Fig. [8](#prp2249-fig-0008){ref-type="fig"}H). These results suggest that G*α* interactions at the GPR motif do not alter RGS domain function on a separate G protein.

Discussion {#prp2249-sec-0014}
==========

The primary goal of this work was to compare and determine the effects of a conventional RGS protein (RGS4) with those of an unconventional RGS protein with two G protein‐binding domains (RGS14) on G protein activation/deactivation kinetics and G*βγ* signaling. Many conventional RGS proteins interact directly with the receptor/G protein complex by one or more mechanisms to deactivate both G*α* and G*βγ* signaling (Neitzel and Hepler [2006](#prp2249-bib-0028){ref-type="ref"}). RGS14, by contrast, with both a GPR motif and an RGS domain, exerts unique regulation of G protein signaling that has yet to be fully elucidated. Our previous work revealed that RGS14 can bind two G*α* subunits simultaneously, one active G*α*‐GTP at the RGS domain and one inactive G*α*‐GDP at the GPR motif (Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}). In vitro GTPase assays showed that binding of inactive G*α*‐GDP to the GPR motif does not alter the GAP function of the RGS domain (Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}). While this biochemical assessment provided key insights into the mechanics of RGS14 function, how this information would translate to a cellular environment remained unclear. Moreover, these previous findings did not clarify the effects RGS14 regulation of G*α* would have on G*βγ* signaling. Two possible models exist: (1) the RGS domain of RGS14 could operate independently of the GPR motif and serve as a dedicated GAP that deactivates both G*α* and G*βγ* signaling, similar to other conventional RGS proteins, or (2) the RGS domain and the GPR motif could work cooperatively to deactivate and capture a single inactive G*α*i‐GDP, thereby preventing G protein heterotrimer reassociation and prolonging G*βγ* signaling. Our findings in this study are most consistent with the former model, and suggest that the GPR motif is functionally silent in regulating RGS14 GAP activity in a cellular context. This model suggests that RGS14 may exist as a preformed dimeric complex with G*α*i‐GDP at membranes, positioned to act as a GAP on a separate nearby GPCR/G protein signaling event without prolonging G*βγ* signaling.

G*α*o releases more free G*βγ* than G*α*i1 {#prp2249-sec-0015}
------------------------------------------

Upon examining ΔBRET in our reconstituted GPCR/G protein signaling system, an apparent difference in free G*βγ* released by G*α*o and G*α*i1 emerged. Activation of G*α*o‐containing heterotrimers resulted in an approximately threefold greater increase in G*βγ*‐GRK BRET activity (indicative of release of free G*βγ*) than that observed for activation of G*α*i1‐containing heterotrimers. Similar studies examining G*βγ* release have also demonstrated larger maximum ΔBRET signals from G*α*o than G*α*i1 transfected with similar G*α*:G*βγ* ratios as we present here (Masuho et al. [2015b](#prp2249-bib-0024){ref-type="ref"}). Reasons for this difference in free G*βγ* release from the two different G*α* are unclear, but could be due to differential delivery of G*α*o heterotrimers to the plasma membrane than G*α*i1. Alternatively, differential coupling efficiency of heterotrimers with the GPCR or differential dissociation of heterotrimers after activation could underlie these differences. These possibilities are not mutually exclusive and both may contribute to the phenomena observed. In a study examining the release of free G*βγ* dimers from G*α*o and G*α*i1, G*βγ* was more readily released from G*α*o activation suggesting G*α*i1 may have a higher affinity for G*βγ* than G*α*o (Digby et al. [2008](#prp2249-bib-0008){ref-type="ref"}). In vitro analysis of G protein affinities revealed G*α*i1 has a higher affinity for G*βγ* than G*α*o (Sarvazyan et al. [2002](#prp2249-bib-0031){ref-type="ref"}). Thus, the differences we observe in free G*βγ* release may be due to the higher affinity of G*α*i1 for G*βγ* than G*α*o.

RGS14 and RGS4 both limit the release of free G*βγ* and accelerate the deactivation rates of G*α*o‐ and G*α*i1‐containing G proteins {#prp2249-sec-0016}
------------------------------------------------------------------------------------------------------------------------------------

We examined the effects of a conventional RGS protein, RGS4, and an unconventional RGS protein, RGS14, on the kinetics of G protein heterotrimer dissociation and reassociation. Somewhat surprisingly, RGS14 exhibited similar effects as RGS4 on G protein subunit kinetics, despite having a second distinct G protein‐binding domain in addition to the RGS domain. Increased expression of either RGS protein significantly inhibited the release of free G*βγ* (ΔBRET). Moreover, increased RGS expression resulted in increased rates of deactivation for both G*α*o and G*α*i1 proteins.

The BRET signal amplitude is governed by the balance of activation (release of G*βγ* from G*α*), and deactivation of G protein heterotrimers, measured indirectly as release of G*βγ* from the GRK BRET sensor. As RGS proteins stimulate G protein GTPase activity, RGS proteins accelerate the deactivation rate and lower the ΔBRET signal as fewer G proteins are active upon addition of agonist. This was observed in the present work since increased RGS expression resulted in decreased ΔBRET. The increase in deactivation rate due to RGS14 was relatively small (approximately twofold), especially when compared to the profound (more than 100‐fold) increase in the rate of G*α* GTPase stimulated by RGS proteins in biochemical assays using pure proteins (Ross and Wilkie [2000](#prp2249-bib-0030){ref-type="ref"}). Several factors likely contribute to this discrepancy. At a technical level, our assays were limited by the amount of RGS14 that could be transfected (30 ng) because additional RGS14 greatly reduced the ΔBRET so that deactivation curves could not be reliably fit, thereby limiting our interpretation. Other cellular factors also must be considered. First, the GTPase acceleration by RGS defined biochemically compares a G*α* in the absence of RGS to one in the presence of RGS. However, our cell‐based studies compare a G protein with endogenous RGS to a G protein with endogenous plus additional exogenous RGS. Therefore, the basal G*α* GTPase state in HEK cells is not RGS‐null, and the basal deactivation rate of G*α* in cells is faster due to the presence of endogenous RGS (Lambert et al. [2010](#prp2249-bib-0021){ref-type="ref"}). Thus, the relatively small increase in deactivation rate (twofold) we observe in HEK cells with addition of recombinant RGS14 or RGS4 is very similar to the modest effects previously reported. Second, the G*βγ*‐GRK BRET assay does not directly measure G*α* GTPase activity and heterotrimer reassociation, but rather it directly measures G*βγ* association with and dissociation from the GRK BRET sensor. Thus, one possible contribution to the slow G*βγ* deactivation rate may be that the rate of release of G*βγ* from GRK is slower than the rate of RGS‐directed formation of G*α*‐GDP. Consistent with this idea, the rate of deactivation of GIRK channels is increased only four‐ to fivefold by RGS4 (Doupnik et al. [2004](#prp2249-bib-0009){ref-type="ref"}), in this case also reflecting the rate of dissociation of G*βγ* from GIRK, and is much slower than the accelerated rate of G*α*‐GTP hydrolysis stimulated by RGS4 (Ross and Wilkie [2000](#prp2249-bib-0030){ref-type="ref"}). Lastly, the BRET tag on the G*βγ* may impede heterotrimer reassociation and/or the presence of endogenous G*βγ* may compete with recombinant protein.

Given these caveats, we also determined whether the increase in rate of G protein deactivation by RGS14 was due solely to the RGS domain or had contributions from the GPR motif. Expression of an RGS‐null mutant of RGS14 (E92A/N93A) abolished the increase in deactivation rate observed with RGS14‐WT, whereas expression of a GPR‐null mutant of RGS14 (Q515A/R516A) did not alter the deactivation rate observed with RGS14‐WT. These results highlight the fact that the deactivation of G protein signaling by RGS14 is due solely to the RGS domain, and that the GPR motif does not slow reassociation of heterotrimers. We postulate that the RGS14 association with G*α*i1‐GDP via the GPR motif likely serves a primary role of stably anchoring RGS14 to membranes (Shu et al. [2007](#prp2249-bib-0032){ref-type="ref"}), but plays no role in the regulation of RGS14 GAP activity (Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}).

RGS14 does not alter the formation of G*α*i1 heterotrimers with G*βγ* {#prp2249-sec-0017}
---------------------------------------------------------------------

Binding of G*α*i1 by the RGS14 GPR motif and G*βγ* are mutually exclusive (Kimple et al. [2002](#prp2249-bib-0020){ref-type="ref"}; Mittal and Linder [2004](#prp2249-bib-0025){ref-type="ref"}; Shu et al. [2007](#prp2249-bib-0032){ref-type="ref"}). Previous in vitro studies have suggested that the RGS14 GPR motif cannot displace G*βγ* from a preformed G*αβγ* heterotrimer (Mittal and Linder [2006](#prp2249-bib-0026){ref-type="ref"}). However, other studies have suggested that an isolated RGS14 GPR motif peptide can prevent heterotrimer assembly in vitro, and alter G*βγ* signaling to GIRK channels in response to D2S dopamine receptor activation (Webb et al. [2005](#prp2249-bib-0037){ref-type="ref"}). To examine whether co‐expression of RGS14 alters the basal formation of G*αβγ* heterotrimers in cells, we examined basal BRET prior to agonist stimulation. Since the RGS14 GPR motif is selective for G*α*i1 (Hollinger et al. [2001](#prp2249-bib-0016){ref-type="ref"}), we expected co‐expression of RGS14 to disrupt basal BRET in G*α*i1‐expressing cells, but not G*α*o‐expressing cells. However, in cells expressing either G*α*i1 or G*α*o, we saw no difference in basal BRET upon co‐expression of RGS14. These results suggest that RGS14 does not alter the assembly of G*αβγ* heterotrimers in live cells, consistent with previous observations with purified proteins (Mittal and Linder [2006](#prp2249-bib-0026){ref-type="ref"}).

Although RGS14 does not appear to disrupt the basal formation of G*αβγ* heterotrimers, it may be able to bind G*α*‐GDP following a GPCR‐mediated signaling event. As the GPR motif does not bind G*α*o (Hollinger et al. [2001](#prp2249-bib-0016){ref-type="ref"}), we did not see a difference in return to baseline BRET in cells expressing G*α*o (Fig. [4](#prp2249-fig-0004){ref-type="fig"}). Surprisingly, we also did not see a difference in return to baseline in cells expressing G*α*i1 (Fig. [5](#prp2249-fig-0005){ref-type="fig"}). These results suggest that RGS14 does not interfere with heterotrimer assembly prior to or after agonist stimulation, and does not prolong G*βγ* signaling, suggesting that RGS14 may be prebound to the plasma membrane by a distinct G*α*i that is bound to the GPR motif and uninvolved with the receptor signaling event.

Previous experiments demonstrating the RGS14 GPR motif could disrupt heterotrimer formation were performed with isolated GPR motif peptides (Webb et al. [2005](#prp2249-bib-0037){ref-type="ref"}; Mittal and Linder [2006](#prp2249-bib-0026){ref-type="ref"}), while the present experiments were performed with the full‐length RGS14 protein. It is possible that an isolated GPR motif behaves differently than a GPR motif in a full‐length RGS14 protein. The effect of an isolated RGS14 GPR motif on G*βγ* release was not investigated in this study because a mammalian truncation expression construct containing only the GPR motif does not express well in HEK 293 cells (unpubl. obs.). Moreover, our investigation focused on the full‐length RGS14 as we attempt to understand the interdomain regulation of G proteins by RGS14.

Interactions of the GPR motif with G*α*i1 does not alter RGS14 GAP activity of the RGS domain toward G*α*o {#prp2249-sec-0018}
----------------------------------------------------------------------------------------------------------

The presence of a second G protein‐binding motif (GPR) in RGS14 presents a unique mechanism for further regulation of G protein signaling in addition to the RGS domain. Previously we have demonstrated that upon co‐expression of inactive G*α*i1, RGS14 is targeted to the plasma membrane (Shu et al. [2007](#prp2249-bib-0032){ref-type="ref"}; Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}) where it can associate with GPCRs via G*α* (Vellano et al. [2011](#prp2249-bib-0035){ref-type="ref"}). We previously proposed that GPR associations with membrane‐bound G proteins could facilitate RGS14 RGS GAP activity by physically bringing RGS14 to the site of G protein signaling (Brown et al. [2015b](#prp2249-bib-0004){ref-type="ref"}). Recent evidence suggests that membrane association of R7 RGS family members, specifically RGS7 and RGS9‐2, potentiated the GAP effect of the RGS domain (Muntean and Martemyanov [2016](#prp2249-bib-0027){ref-type="ref"}). Results obtained in this study suggest that RGS14 association with the plasma membrane via the GPR motif does not enhance the deactivation kinetics of RGS14‐accelerated G protein deactivation (Fig. [8](#prp2249-fig-0008){ref-type="fig"}). Taken together, these results suggest that the RGS domain and GPR motif function independently from one another, perhaps on distinct G*α* -- one involved with receptor signaling and a second that anchors RGS14 to the plasma membrane.

While we did not observe a change in G*α*o kinetics upon co‐expression of G*α*i1, our studies do not address the possibility that our treatment of cells with pertussis toxin may have altered the ability of G*α*i1 to recruit RGS14 to the site of G protein activation. Previously, we and others have shown that GPR‐containing proteins can associate with GPCRs (Vellano et al. [2011](#prp2249-bib-0035){ref-type="ref"}; Robichaux et al. [2015](#prp2249-bib-0029){ref-type="ref"}), an association that is dependent on G*α*. Pertussis toxin‐mediated uncoupling of receptor/G*α*i1 may not optimally position RGS14:G*α*i1 complexes to favor interaction with GPCRs. However, given that these studies were completed with expressed recombinant proteins, the density of G proteins at the plasma membrane likely favored RGS14:G*α*i1 complex placement near GPCRs.

Concluding remarks {#prp2249-sec-0019}
------------------

Here, we compared the effects of distinct RGS proteins on G*α*i/o heterotrimeric signaling. Our results indicate that the conventional RGS protein RGS4 and the unconventional RGS14 each similarly limit the release of free G*βγ* and accelerate the deactivation rate of G*α*. The GAP effect of RGS14 is solely due to the RGS domain since binding of an inactive G protein to the GPR motif does not alter the GAP effect of the RGS domain. The results presented here suggest the RGS domain and GPR motif do not coordinate to regulate G protein signaling. We propose that despite RGS14 containing two G*α* interaction sites, the GPR motif serves to anchor RGS14 in complex with G*α*i‐GDP at membranes independently of G*βγ* and is functionally silent with regard to RGS domain‐mediated GAP activity.
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